149 related articles for article (PubMed ID: 34757467)
1. Epstein-Barr virus-positive diffuse large B-cell lymphoma after frontline brentuximab vedotin treatment of classical Hodgkin lymphoma.
Tse E; Au-Yeung R; Chau D; Hwang YY; Loong F; Kwong YL
Ann Hematol; 2022 May; 101(5):1149-1152. PubMed ID: 34757467
[No Abstract] [Full Text] [Related]
2. Synchronous Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly and Epstein-Barr virus-positive classical Hodgkin lymphoma.
Hwang YY; Leung AY; Lau WH; Loong F; So JC; Tse E; Kwong YL
Histopathology; 2011 Aug; 59(2):352-5. PubMed ID: 21884219
[No Abstract] [Full Text] [Related]
3. A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly.
Wang E; Papavassiliou P; Sebastian S
Pathol Res Pract; 2012 Jun; 208(6):363-7. PubMed ID: 22572037
[TBL] [Abstract][Full Text] [Related]
4. Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features.
Zibara V; Sen F; Scordo M; Falchi L
Leuk Lymphoma; 2022 Dec; 63(13):3241-3244. PubMed ID: 36120859
[No Abstract] [Full Text] [Related]
5. Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab.
Meister MT; Voss S; Schwabe D
Pediatr Blood Cancer; 2015 Nov; 62(11):2018-20. PubMed ID: 26109475
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas.
Kim M; Lee JO; Koh J; Kim TM; Lee JY; Jeon YK; Keam B; Kim DW; Lee JS; Heo DS
Haematologica; 2021 Aug; 106(8):2277-2280. PubMed ID: 33792222
[No Abstract] [Full Text] [Related]
7. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin.
Guan T; Lo M; Young R; Ai W; Boulbol F; Mouanoutoua H; Chu R; Andreadis C; Kaplan L; Abdulhaq H; Fakhri B
Leuk Lymphoma; 2022 Dec; 63(12):3008-3011. PubMed ID: 35875857
[No Abstract] [Full Text] [Related]
9. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
[TBL] [Abstract][Full Text] [Related]
10. Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases.
Wang Y; Wang Z; Wei C; Zhao D; Zhang Y; Wang W; Zhang W; Zhou D
Ann Hematol; 2023 Oct; 102(10):2973-2975. PubMed ID: 37522969
[No Abstract] [Full Text] [Related]
11. A fulminant case of classical Hodgkin lymphoma: A diagnostic dilemma of Epstein-Barr virus-positive large B-cell neoplasms.
Ichimata S; Kobayashi M; Ohya M; Otsuki T; Yanagisawa K; Tateishi K; Kato A; Matsuo A; Kanno H
Pathol Int; 2019 Jul; 69(7):407-413. PubMed ID: 31215109
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin-induced pancreatitis in lymphoma: a pharmacovigilance study.
Moore DC; Elmes JB; Strassels SA; Patel JN
Leuk Lymphoma; 2022 Jul; 63(7):1768-1769. PubMed ID: 35249444
[No Abstract] [Full Text] [Related]
13. Epstein-Barr virus-positive diffuse large B-cell lymphoma in children: a disease reminiscent of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
Uccini S; Al-Jadiry MF; Scarpino S; Ferraro D; Alsaadawi AR; Al-Darraji AF; Moleti ML; Testi AM; Al-Hadad SA; Ruco L
Hum Pathol; 2015 May; 46(5):716-24. PubMed ID: 25704629
[TBL] [Abstract][Full Text] [Related]
14. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Oak E; Bartlett NL
Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
[TBL] [Abstract][Full Text] [Related]
15. Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus.
Foo WC; Huang Q; Sebastian S; Hutchinson CB; Burchette J; Wang E
Hum Pathol; 2010 Dec; 41(12):1802-8. PubMed ID: 20869749
[TBL] [Abstract][Full Text] [Related]
16. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study.
Izutsu K; Ogura M; Tobinai K; Hatake K; Sakamoto S; Nishimura M; Hoshino M
Int J Hematol; 2021 Mar; 113(3):404-412. PubMed ID: 33392974
[TBL] [Abstract][Full Text] [Related]
17. Comment on: Treatment of EBV-Associated Nodular Sclerosing Hodgkin Lymphoma in a Patient With Ataxia Telangiectasia With Brentuximab Vedotin and Reduced COPP Plus Rituximab.
Zielen S
Pediatr Blood Cancer; 2016 May; 63(5):946. PubMed ID: 26719151
[No Abstract] [Full Text] [Related]
18. Synchronous biphenotypic Richter syndrome with Epstein-Barr virus-positive nodal classical Hodgkin lymphoma and bone marrow diffuse large B-cell lymphoma.
Cheah CY; Spagnolo D; Frost F; Cull G
Histopathology; 2016 Oct; 69(4):707-10. PubMed ID: 27079556
[No Abstract] [Full Text] [Related]
19. Reply to Comment on: Treatment of EBV-Associated Nodular Sclerosing Hodgkin Lymphoma in a Patient With Ataxia Telangiectasia With Brentuximab Vedotin and Reduced COPP Plus Rituximab.
Meister MT; Voss S; Schwabe D
Pediatr Blood Cancer; 2016 May; 63(5):947. PubMed ID: 26739927
[No Abstract] [Full Text] [Related]
20. Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?
Goyal SD; Bartlett NL
Curr Hematol Malig Rep; 2012 Sep; 7(3):179-85. PubMed ID: 22669711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
